Registry of Patients With Remote Posterior cErebral Hemorrhage Following Reperfusion Treatment in Ischemic Stroke (HEROES-CAT)

HEROES Registry: Registry of Patients With Remote Posterior cErebral Hemorrhage Following Reperfusion Treatment in Ischemic Stroke in Catalonia

Introduction Remote cerebral hemorrhage following reperfusion treatment in ischemic stroke is rare (1.3-3.7% of all treated strokes) and is associated with worse functional and vital prognosis. Multicenter observational studies suggest that amyloid angiopathy may be one of the main risk factors for remote hemorrhage. Currently, it is unknown what happens to those patients with remote hemorrhage beyond 3 months of follow-up in terms of risk/benefit balance when receiving antiplatelet or anticoagulant therapy, as well as from a cognitive point of view. Considering an analogy with amyloid angiopathy, the hypothesis is that those patients with remote hemorrhage have a higher risk of intracranial hemorrhage during follow-up when receiving stroke secondary prevention, and will also present greater cognitive deterioration during long-term follow-up.

Main Objectives

• To explore the frequency and risk factors for intracranial hemorrhage during follow-up of patients with remote cerebral hemorrhage.
• To explore the frequency and progression of cognitive deterioration during follow-up in patients with remote cerebral hemorrhage.

Methodology Observational, prospective, multicenter registry with a population-based case-control design of consecutive patients with remote hemorrhage following reperfusion therapy in acute ischemic stroke. Inclusion criteria: Diagnosis of ischemic stroke with age greater than or equal to 18 years who has remote cerebral hemorrhage after receiving reperfusion therapy in the acute phase. Exclusion criteria: Lack of basic data (age, sex, neuroimaging data) or telephone for follow-up. The cases will be those patients with remote hemorrhage. For each case included, 4 consecutive controls will be included (2 with local parenchymal hemorrhagic transformation and 2 without hemorrhagic transformation). The data will be filled out within the (Codi Ictus de CATalunya) CICAT registry form (currently mandatory in all stroke centers in Catalonia) to which additional variables will be added. Telephone follow-up will be conducted at 3, 12, and 24 months.

Main study variable:

• Any type of spontaneous or traumatic intracranial hemorrhage during a 24-month follow-up.
• Score on the "Short Informant Questionnaire" scale (a validated 17-question questionnaire to be conducted over the phone, where a score higher than 57 points indicates cognitive impairment).

Expected sample size during a 2-year recruitment period: 105-300 patients (considering the participating centers to date).

Additional information. This study is endorsed by the "Pla Director de la Malaltia Vascular Cerebral" in Catalonia.

Participating Centers. Participation offers have been sent to the 28 hospitals in the hospital network of Catalonia with the capacity to administer intravenous fibrinolysis. Positive responses have been received from 13 of them so far. In case the project is accepted by the (Comité Ético de Investigación Clínica) CEIC Sant Pau, the centers that have not responded will be contacted again to obtain their participation.

Study Overview

• Status: Recruiting
• Conditions: Ischemic Stroke; Intracranial Hemorrhages; Hemorrhagic Transformation Stroke

• Study Type: Observational
• Enrollment (Anticipated): 250

Contacts and Locations

• Study Contact: Name: Luis Prats Sanchez, MD PhD; Phone Number: +34935565986; Email: lpratss@santpau.cat

Study Locations

• Spain
  • Cataluña
    • Barcelona, Cataluña, Spain
      • Recruiting
      • Hospital De La Santa Creu I Sant Pau
      • Contact: Luis Prats-Sanchez, PhD; Phone Number: +34935565986; Email: lpratss@santpau.cat
      • Contact: Phone Number: +34935565986

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The study outlines a four-step process to identify and select cases for a study on remote hemorrhages with or without local hemorrhagic transformation. The first step is to identify cases by evaluating control neuroimaging, and if there are doubts, investigators can seek consensus decision-making. The second step is to select four controls for each case, two without hemorrhagic transformation and two with type 2 hemorrhagic transformation. The third step involves completing the CICAT registry form and additional variables, some of which are optional. The fourth and final step is to conduct telephone follow-up at 3, 12, and 24 months to collect variables of interest in relation to the study's objectives.

Description

Inclusion Criteria:

1. Patients who meet the criteria for being a case (remote hemorrhage) or control according to the definition of Heidelberg hemorrhagic transformations
2. Age 18 or older
3. Definite diagnosis of ischemic stroke (intracranial large vessel occlusion, compatible lesion on neuroimaging)
4. Administration of a fibrinolytic drug associated or not with endovascular therapy (intravenous or local)
5. Availability of a control brain imaging before the first 36 hours from reperfusion treatment.

Exclusion Criteria:

• Lack of basic data (age, sex, follow-up neuroimaging, contact phone number for follow-up).

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
No hemorrhagic transformation; Patients with ischemic stroke treated with intravenous thrombolysis and no hemorrhagic transformation (IH1 or IH2 are allowed)
Local hemorragic transformation; Patients with ischemic stroke treated with intravenous thrombolysis and hemorrhagic transformation PH1 or PH2
Remote hemorrhage; Patients with ischemic stroke treated with intravenous thrombolysis and remote hemorrhage in areas without evident ischemia (rPH)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Explore the frequency and risk factors of intracranial hemorrhage during follow-up in patients with remote cerebral hemorrhage	Describe the frequency, rate and adjusted hazard ratio	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Explore the frequency of ischemic stroke, intracerebral hemorrhage, intracranial hemorrhage, and any cerebrovascular event in patients with remote cerebral hemorrhage.	Describe the frequency, rate and adjusted hazard ratio	24 months
Investigate the net benefit of preventive treatment in patients with remote cerebral hemorrhage (composite of ischemic stroke and intracranial hemorrhage).	Evaluate the rate and adjusted hazard ratio of ischemic and hemorrhagic events	24 months
Explore the socio-functional status of patients with remote cerebral hemorrhage using the modified Rankin Scale during follow-up.	Describe the proportion of patients with favorable functional outcome measured with modified Rankin Scale (favorable is the score is 0-2)	24 months
Explore vascular mortality and overall mortality in patients with remote cerebral hemorrhage during follow-up.	Describe the frequency, rate and adjusted hazard ratio	24 months
Explore cognitive impairment follow-up	IQCODE brief test >56 points	24 months

Collaborators and Investigators

• Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• Collaborators: Hospital Clinic of Barcelona; Germans Trias i Pujol Hospital; Hospital Arnau de Vilanova; Hospital del Mar; Hospital Universitari de Bellvitge; Hospital Vall d'Hebron; Hospital de Granollers; Hospital de Sant Joan Despí Moisès Broggi; Hospital Parc Taulí, Sabadell; University Hospital of Girona Dr.Josep Trueta; Agència de Qualitat i Avaluació Sanitàries; Consorci Sanitari del Garraf
• Investigators: Principal Investigator: Luis Prats Sanchez, MD PhD, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2021
• Primary Completion (Anticipated): May 1, 2025
• Study Completion (Anticipated): May 1, 2025

Study Registration Dates

• First Submitted: May 4, 2023
• First Submitted That Met QC Criteria: May 12, 2023
• First Posted (Actual): May 23, 2023

Study Record Updates

• Last Update Posted (Actual): May 23, 2023
• Last Update Submitted That Met QC Criteria: May 12, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Secondary prevention; Ischemic stroke; Thrombolysis; Hemorrhagic transformation stroke
• Additional Relevant MeSH Terms: Pathologic Processes; Necrosis; Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Brain Ischemia; Infarction; Brain Infarction; Stroke; Ischemic Stroke; Ischemia; Hemorrhage; Cerebral Infarction; Intracranial Hemorrhages; Cerebral Hemorrhage
• Other Study ID Numbers: IIBSP-HER-2020-79

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No